Pharmaceutical - Anti-virals

Filter

Current filters:

Anti-virals

Popular Filters

51 to 75 of 319 results

ViiV Healthcare gains FDA approval for HIV drug Triumeq

ViiV Healthcare gains FDA approval for HIV drug Triumeq

23-08-2014

The US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine…

Anti-viralsGlaxoSmithKlinePfizerPharmaceuticalRegulationShionogiTriumeqUSAViiV Healthcare

Hera Therapeutics’ HTI-1968 shuts down HPV that causes most cervical cancer

Hera Therapeutics’ HTI-1968 shuts down HPV that causes most cervical cancer

23-08-2014

Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being…

Anti-viralsHera Therapeuticshti-1968PharmaceuticalResearchWomen's Health

Animal data show positive results in Marburg virus with Tekmira’s LNP

Animal data show positive results in Marburg virus with Tekmira’s LNP

21-08-2014

Canadian RNA interference (RNAi) therapeutics developer Tekmira Pharmaceuticals has highlighted the publication…

Anti-viralsPharmaceuticalResearchTekmira PharmaceuticalsTKM-Ebola

Achillion soars on positive mid-stage hep C drug combo trial

Achillion soars on positive mid-stage hep C drug combo trial

17-08-2014

US drugmaker Achillion saw its share rocket 18.4% to a 52-week high of $9.99 in pre-market trading on…

ACH-3102AchillionAnti-viralsHepatitis C virusPharmaceuticalResearchsofosbuvirSovaldiUSA

Sanofi Pasteur announces positive results for Fluzone’s higher dose

Sanofi Pasteur announces positive results for Fluzone’s higher dose

14-08-2014

Sanofi Pasteur, the vaccines division of French drug major Sanofi, has found that Fluzone High-Dose was…

Anti-viralsFluzonePharmaceuticalResearchSanofiSanofi PasteurUSAVaccinationVaccines

Ethical considerations for use of unregistered interventions for Ebola viral disease

Ethical considerations for use of unregistered interventions for Ebola viral disease

12-08-2014

In reaction to West Africa is experiencing the largest, most severe and most complex outbreak of Ebola…

Anti-viralsClinical researchHealthcarePharmaceuticalRegulationRest of the WorldTropical diseases

US court orders SIGA to pay PharmAthene lump sum expectation damages

US court orders SIGA to pay PharmAthene lump sum expectation damages

11-08-2014

USA-based biodefense company PharmAthene says that, on Friday, the Delaware Court of Chancery issued…

Anti-viralsDelaware Court of ChanceryFinancialLegalPharmaceuticalPharmAtheneSIGA TechnologiesTecovirimatUSA

FDA modifies Tekmira's TKM-Ebola clinical hold to partial hold

FDA modifies Tekmira's TKM-Ebola clinical hold to partial hold

08-08-2014

Canadian RNA interference (RNAi) therapeutics developer Tekmira Pharmaceuticals revealed yesterday that…

Anti-viralsEbolaMicrobiologyPharmaceuticalRegulationResearchTekmira PharmaceuticalsTKM-EbolaUS Food and Drug AdministrationUSA

Biota tanks as flu drug candidate disappoints

Biota tanks as flu drug candidate disappoints

04-08-2014

USA-based Biota Pharmaceuticals saw its shares slump 29% to a record low of $2.29 on Friday, after the…

Anti-viralsAntibiotics and Infectious diseasesBiota PharmaceuticalsFinancialPharmaceuticalResearchUSA

Janssen’s simeprevir for hepatitis C shows good efficacy in Phase II trial

Janssen’s simeprevir for hepatitis C shows good efficacy in Phase II trial

31-07-2014

Some 92% of genotype 1 chronic hepatitis C virus (HCV) adult patients treated with US health care giant…

Anti-viralsGilead SciencesIrelandJanssenPharmaceuticalResearchsimeprevirsofosbuvir

Novartis’ Bexsero has high uptake in first widespread public vaccination program against meningitis B

Novartis’ Bexsero has high uptake in first widespread public vaccination program against meningitis B

29-07-2014

Swiss drug major Novartis has announced initial results from a large-scale vaccination campaign using…

Anti-viralsBexseroCanadaMeningitis BNovartisPharmaceuticalResearch

Expensive new hepatitis C drugs are worth the investment

Expensive new hepatitis C drugs are worth the investment

21-07-2014

The debate over the high price of new Hepatitis C Virus (HCV) drugs has focused on the price per pill,…

Anti-viralsCVS CaremarkGilead SciencesHepatitis CPharmaceuticalPricingSovaldiUSA

Australian Health Ministers sign on to end HIV transmissions by 2020

Australian Health Ministers sign on to end HIV transmissions by 2020

21-07-2014

All Australian Health Ministers have committed to working towards the virtual elimination of new Australian…

AIDSAnti-viralsAustraliaHealthcareHIV/AIDSPharmaceuticalPoliticsRegulation

Médecins Sans Frontières says countries are being priced out of HIV drugs and testing

Médecins Sans Frontières says countries are being priced out of HIV drugs and testing

21-07-2014

International medical humanitarian organization Médecins Sans Frontières has said that high prices…

Anti-viralsAntiretroviral drugHIVHIV/AIDSMSFPharmaceuticalPricing

Report: US state governments may spend $55 billion on hepatitis C drugs

Report: US state governments may spend $55 billion on hepatitis C drugs

17-07-2014

State legislatures in the USA will need to find billions in their budgets to purchase costly new hepatitis…

Anti-viralsExpress ScriptsFinancialGilead SciencesHealthcarePharmaceuticalSovaldiUSA

Drug-treated hepatitis C population to more than double by 2016

Drug-treated hepatitis C population to more than double by 2016

16-07-2014

The hepatitis C virus population is already large, with 2 million diagnosed, chronically infected cases…

Anti-viralsCytokinesDaklinzaDecision Resources GroupEuropeHepatitis CInterferonJapanMarkets & MarketingPharmaceuticalUSA

Bristol-Myers hepatitis C treatment Daklinza+Sunvepra OKed in Japan

Bristol-Myers hepatitis C treatment Daklinza+Sunvepra OKed in Japan

07-07-2014

The Japanese Ministry of Health, Labor and Welfare has approved Daklinza (daclatasvir), a potent, pan-genotypic…

Anti-viralsBristol-Myers SquibbDaklinzaDaklinza+SunvepraJapanPharmaceuticalRegulationSunvepra

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

03-07-2014

USA-based Isis Pharmaceuticals has earned yet another $1 million payment from UK pharma giant GlaxoSmithKline,…

Anti-viralsFinancialGlaxoSmithKlineIsis PharmaceuticalsPharmaceuticalResearch

New report calls on governments to implement national policies on hepatitis C

New report calls on governments to implement national policies on hepatitis C

25-06-2014

A report published by The Economist Intelligence Unit (EIU) has revealed that many countries around the…

Anti-viralsGlobalHealthcareJanssenPharmaceutical

New treatments to boost hepatitis C market to $19.2 billion by 2016

New treatments to boost hepatitis C market to $19.2 billion by 2016

24-06-2014

The launch of interferon-free regimens is expected to boost the hepatitis C market from $2.9 billion…

Anti-viralsAntiviralsBusiness FinanceCytokinesDatamonitorGilead SciencesGlobalMajorMarkets & MarketingPharmaceuticalSovaldi

Boehringer Ingelheim pulls out of hepatitis C drug development

Boehringer Ingelheim pulls out of hepatitis C drug development

23-06-2014

German family-owned pharma major Boehringer Ingelheim revealed that, following a re-evaluation of its…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

51 to 75 of 319 results

Back to top